Valuation: Incyte Corporation

Capitalization 20.15B 17.23B 15.99B 15B 27.82B 1,845B 29.79B 184B 72.62B 872B 75.55B 74B 3,186B P/E ratio 2025 *
16.5x
P/E ratio 2026 * 15.2x
Enterprise value 16.15B 13.81B 12.82B 12.02B 22.31B 1,479B 23.88B 147B 58.22B 699B 60.57B 59.33B 2,554B EV / Sales 2025 *
3.24x
EV / Sales 2026 * 2.64x
Free-Float
97.51%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.58%
1 week-2.03%
Current month+5.09%
1 month+3.07%
3 months+18.90%
6 months+54.05%
Current year+5.09%
More quotes
1 week 100
Extreme 100
108.58
1 month 97.63
Extreme 97.63
112.29
Current year 97.94
Extreme 97.94
112.29
1 year 53.56
Extreme 53.56
112.29
3 years 50.27
Extreme 50.27
112.29
5 years 50.27
Extreme 50.27
112.29
10 years 50.27
Extreme 50.27
153.15
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 49 2025-09-15
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.60%-2.03%+41.28%+24.34% 20.15B
+0.89%-2.16%+7.27%+1.08% 75.29B
-2.45%+87.30%+87.30%+87.30% 60.19B
-0.33%+1.61%-35.86%-41.10% 57.45B
-1.37%-2.58%+38.20%+228.36% 57.16B
+3.49%+0.89%+21.17%-41.49% 24.26B
-0.60%-7.44%+166.34%+91.88% 18.51B
-22.35%-21.78%+17.27%+998.53% 17.42B
+11.88%+18.01%+33.44%-75.68% 16.8B
+0.20%-1.13%+113.47%+803.99% 14.88B
Average -0.93%-4.06%+48.99%+207.72% 36.21B
Weighted average by Cap. -0.73%-3.03%+35.62%+125.09%
See all sector performances

Financials

2025 *2026 *
Net sales 4.98B 4.26B 3.95B 3.71B 6.87B 456B 7.36B 45.34B 17.94B 215B 18.67B 18.29B 787B 5.53B 4.73B 4.39B 4.12B 7.63B 506B 8.18B 50.36B 19.93B 239B 20.73B 20.31B 874B
Net income 1.26B 1.07B 996M 935M 1.73B 115B 1.86B 11.44B 4.53B 54.35B 4.71B 4.61B 199B 1.35B 1.16B 1.07B 1.01B 1.87B 124B 2B 12.32B 4.88B 58.56B 5.07B 4.97B 214B
Net Debt -3.99B -3.42B -3.17B -2.97B -5.52B -366B -5.91B -36.39B -14.4B -173B -14.98B -14.67B -632B -5.56B -4.75B -4.41B -4.14B -7.68B -509B -8.22B -50.63B -20.03B -241B -20.84B -20.42B -879B
More financial data * Estimated data
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.3%); - royalties (13.7%); - income from research and cooperation agreements (1%).
Employees
2,617
More about the company
Date Price Change Volume
26-01-21 103.85 $ +1.20% 655,349
26-01-20 102.62 $ -3.38% 2,205,966
26-01-16 106.21 $ +0.92% 1,696,253
26-01-15 105.24 $ -0.67% 1,571,769
26-01-14 105.95 $ +2.44% 2,128,350

Delayed Quote Nasdaq, January 21, 2026 at 02:08 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
102.62USD
Average target price
102.33USD
Spread / Average Target
-0.28%
Consensus

Quarterly revenue - Rate of surprise